CA3149041A1 - Compositions et methodes pour le traitement d'infections virales - Google Patents
Compositions et methodes pour le traitement d'infections virales Download PDFInfo
- Publication number
- CA3149041A1 CA3149041A1 CA3149041A CA3149041A CA3149041A1 CA 3149041 A1 CA3149041 A1 CA 3149041A1 CA 3149041 A CA3149041 A CA 3149041A CA 3149041 A CA3149041 A CA 3149041A CA 3149041 A1 CA3149041 A1 CA 3149041A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- nucleic acid
- acid molecule
- viral
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02036—NAD(+)--diphthamide ADP-ribosyltransferase (2.4.2.36)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22062—Caspase-9 (3.4.22.62)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne des procédés et des compositions utilisant des constructions d'acide nucléique recombiné ou une particule du type virus incapable de réplication codant pour une chimiokine, une cytokine ou une protéine induisant l'apoptose, par exemple la Caspase 9 (Casp9), ou d'autres toxines sous une forme ne pouvant pas être transcrite qu'en présence d'une polymérase virale. Ces procédés peuvent être adaptés pour cibler de nombreuses infections virales pour éduire ou éliminer une charge virale, et fournir un traitement fondamentalement différent pour des infections virales.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962893460P | 2019-08-29 | 2019-08-29 | |
US62/893,460 | 2019-08-29 | ||
US202062968387P | 2020-01-31 | 2020-01-31 | |
US62/968,387 | 2020-01-31 | ||
US202062976491P | 2020-02-14 | 2020-02-14 | |
US62/976,491 | 2020-02-14 | ||
US202062985597P | 2020-03-05 | 2020-03-05 | |
US62/985,597 | 2020-03-05 | ||
PCT/US2020/048370 WO2021041787A1 (fr) | 2019-08-29 | 2020-08-28 | Compositions et méthodes pour le traitement d'infections virales |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3149041A1 true CA3149041A1 (fr) | 2021-03-04 |
Family
ID=74686046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3149041A Pending CA3149041A1 (fr) | 2019-08-29 | 2020-08-28 | Compositions et methodes pour le traitement d'infections virales |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4022072A4 (fr) |
JP (1) | JP2022546402A (fr) |
KR (1) | KR20220095183A (fr) |
CN (1) | CN114761566A (fr) |
AU (1) | AU2020335886A1 (fr) |
BR (1) | BR112022003814A2 (fr) |
CA (1) | CA3149041A1 (fr) |
IL (1) | IL290826A (fr) |
MX (1) | MX2022002211A (fr) |
WO (1) | WO2021041787A1 (fr) |
ZA (1) | ZA202202370B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220282279A1 (en) * | 2021-03-06 | 2022-09-08 | Serhat Gumrukcu | Compositions and methods for treating and preventing coronavirus infections |
WO2023220086A1 (fr) * | 2022-05-13 | 2023-11-16 | Suntec Medical, Inc. | Méthode de traitement d'une maladie infectieuse |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7001760B2 (en) * | 2000-04-20 | 2006-02-21 | Wang-Schick Ryu | Hepatitis B virus vectors for gene therapy |
WO2012170431A2 (fr) * | 2011-06-06 | 2012-12-13 | Bluebird Bio, Inc. | Systèmes perfectionnés de commutation génique |
BR112016024458A2 (pt) * | 2014-06-20 | 2017-10-10 | Baruch S Blumberg Inst | antígeno e do hepadnavírus marcado e seu uso em triagem de substâncias antivirais |
-
2020
- 2020-08-28 CA CA3149041A patent/CA3149041A1/fr active Pending
- 2020-08-28 CN CN202080069618.7A patent/CN114761566A/zh active Pending
- 2020-08-28 KR KR1020227010035A patent/KR20220095183A/ko unknown
- 2020-08-28 MX MX2022002211A patent/MX2022002211A/es unknown
- 2020-08-28 WO PCT/US2020/048370 patent/WO2021041787A1/fr active Application Filing
- 2020-08-28 JP JP2022513124A patent/JP2022546402A/ja active Pending
- 2020-08-28 EP EP20858496.1A patent/EP4022072A4/fr active Pending
- 2020-08-28 BR BR112022003814A patent/BR112022003814A2/pt unknown
- 2020-08-28 AU AU2020335886A patent/AU2020335886A1/en active Pending
-
2022
- 2022-02-23 IL IL290826A patent/IL290826A/en unknown
- 2022-02-24 ZA ZA2022/02370A patent/ZA202202370B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2022546402A (ja) | 2022-11-04 |
MX2022002211A (es) | 2022-05-24 |
EP4022072A4 (fr) | 2023-09-06 |
AU2020335886A1 (en) | 2022-03-17 |
CN114761566A (zh) | 2022-07-15 |
BR112022003814A2 (pt) | 2022-05-24 |
IL290826A (en) | 2022-04-01 |
KR20220095183A (ko) | 2022-07-06 |
WO2021041787A1 (fr) | 2021-03-04 |
ZA202202370B (en) | 2022-11-30 |
EP4022072A1 (fr) | 2022-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11419920B2 (en) | Factor VIII sequences | |
CN110770346B (zh) | 多倍体腺相关病毒载体及其制备和使用方法 | |
JP2021036878A (ja) | ワクチン開発のための改善されたb型インフルエンザウイルス複製 | |
EP4218828A3 (fr) | Capsides de variants de virus adéno-associés et leurs procédés d'utilisation | |
KR20160033217A (ko) | 변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도 | |
TW201837170A (zh) | 新穎aav媒介的流感疫苗 | |
US20240066117A1 (en) | Hbv vaccines and methods treating hbv | |
JP2004534543A (ja) | シュードタイプ化アデノ関連ウイルスおよびその使用 | |
CA3149041A1 (fr) | Compositions et methodes pour le traitement d'infections virales | |
US20230133243A1 (en) | Conditioning regimens for in vivo gene therapy | |
EP3624825A1 (fr) | Virus oncolytique recombinant | |
US20210238232A1 (en) | Compositions and methods for treating viral infections | |
US20220282279A1 (en) | Compositions and methods for treating and preventing coronavirus infections | |
US20200123204A1 (en) | Recombinant oncolytic viruses for treatment of metastatic cancers | |
EP2759301A1 (fr) | Utilisation d'un virus de la rougeole infectieux génétiquement modifié présentant de meilleures propriétés pro-apoptotiques (virus MV-deltac) | |
CA3097306A1 (fr) | Virus coxsackie b pour le traitement de tumeurs | |
US20230390383A1 (en) | Replication incompetent influenza vaccine platform for foreign protein delivery | |
JP2023551821A (ja) | ウイルス感染を治療するための方法及び組成物 | |
Pho | Development of a novel therapeutic against coronaviruses | |
Usai | Characterization of a mouse model for the study of hepatitis delta virus infection | |
MY186651A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
NZ733014A (en) | Methods and compositions for treating brain diseases |